Behavior of α-, β-, and γ-cyclodextrins and their derivatives on an in vitro model of blood-brain barrier

被引:84
作者
Monnaert, V
Tilloy, S
Bricout, H
Fenart, L
Cecchelli, R
Monflier, E
机构
[1] Univ Artois, Fac Sci Jean Perrin, CELLIAL Technol, F-62307 Lens, France
[2] Univ Artois, Inst Pasteur Lille, Blood Brain Barrier Lab, EA 2465, F-62307 Lens, France
关键词
D O I
10.1124/jpet.104.067512
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cyclodextrins (CDs) can be envisaged to cure some diseases related to the brain, but the behavior of these compounds toward the blood-brain barrier (BBB) remains largely unexplored to envisage such clinical applications. To fulfill this gap, the toxicity and endothelial permeability for native, methylated, and hydroxypropylated alpha-, beta-, and gamma-CDs have been studied on an in vitro model of BBB. As shown by the endothelial permeability for sucrose and immunofluorescence stainings, the native CDs are the most toxic CDs (alpha- > beta- > gamma-CD). Whereas the chemical modification of beta-CD did not affect the toxicity of this CD, differences are observed for the alpha- and gamma-CD. To determine the origin of toxicity, lipid effluxes on the brain capillary endothelial cells were performed in the presence of native CDs. It was found that alpha-CD removed phospholipids and that beta-CD extracted phospholipids and cholesterol. gamma-CD was less lipid-selective than the other CDs. Finally, the endothelial permeability of each CD has been determined. Surprisingly, no structure/permeability relationship has been observed according to the nature and chemical modifications of CDs.
引用
收藏
页码:745 / 751
页数:7
相关论文
共 34 条
[1]  
ANDERSON IM, 1988, J PSYCHOPHARMACOL, V2, P2
[2]   Cholesteryl-cyclodextrins:: synthesis and insertion into phospholipid membranes [J].
Auzély-Velty, R ;
Perly, B ;
Taché, O ;
Zemb, T ;
Jéhan, P ;
Guenot, P ;
Dalbiez, JP ;
Djedaïni-Pilard, F .
CARBOHYDRATE RESEARCH, 1999, 318 (1-4) :82-90
[3]  
BOOHER J, 1972, Neurobiology (Copenhagen), V2, P97
[4]  
BORNSTEIN MB, 1958, LAB INVEST, V7, P134
[5]   Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease [J].
Camargo, F ;
Erickson, RP ;
Garver, WS ;
Hossain, GS ;
Carbone, PN ;
Heidenreich, RA ;
Blanchard, J .
LIFE SCIENCES, 2001, 70 (02) :131-142
[6]   BETA-CYCLODEXTRIN INTERACTS WITH THE ALZHEIMER AMYLOID BETA-A4 PEPTIDE [J].
CAMILLERI, P ;
HASKINS, NJ ;
HOWLETT, DR .
FEBS LETTERS, 1994, 341 (2-3) :256-258
[7]   In vitro model for evaluating drug transport across the blood-brain barrier [J].
Cecchelli, R ;
Dehouck, B ;
Descamps, L ;
Fenart, L ;
Buée-Scherrer, V ;
Duhem, C ;
Lundquist, S ;
Rentfel, M ;
Torpier, G ;
Dehouck, MP .
ADVANCED DRUG DELIVERY REVIEWS, 1999, 36 (2-3) :165-178
[8]   Drug transport to the brain: Comparison between in vitro and in vivo models of the blood-brain barrier [J].
Dehouck, MP ;
Dehouck, B ;
Schluep, C ;
Lemaire, M ;
Cecchelli, R .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 3 (06) :357-365
[9]   DRUG TRANSFER ACROSS THE BLOOD-BRAIN-BARRIER - CORRELATION BETWEEN INVITRO AND INVIVO MODELS [J].
DEHOUCK, MP ;
JOLLIETRIANT, P ;
BREE, F ;
FRUCHART, JC ;
CECCHELLI, R ;
TILLEMENT, JP .
JOURNAL OF NEUROCHEMISTRY, 1992, 58 (05) :1790-1797
[10]   Use of cyclodextrin for AFM monitoring of model raft formation [J].
Giocondi, MC ;
Milhiet, PE ;
Dosset, P ;
Le Grimellec, C .
BIOPHYSICAL JOURNAL, 2004, 86 (02) :861-869